Global Startups Insights
Lets your startup
Funding News, San Francisco, USA Startup Funding News

Shennon Biotechnologies Raises $12M, Appoints Cyril Konto as CEO

September 14, 2026
By
Loren Baker
Shennon Biotechnologies Raises $12M, Appoints Cyril Konto as CEO

Shennon Biotechnologies, a biotechnology company developing precision immunotherapies for cancer, has raised $12 million in funding from Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures, and Saras Capital.

Existing investors DCVC, Foundation Capital and AV8 Ventures also participated. The latest financing brings ShennonBio’s total funding raised to $25 million.

Founded in 2021, ShennonBio is developing AI-powered technology to discover and develop new cancer treatments. Its platform combines target discovery, high-throughput screening, computational drug design and safety prediction.

“ShennonBio was founded to address fundamental challenges that have limited the development of precision immunotherapies, from identifying differentiated targets and highly functional therapeutic binders to predicting potential safety risks before candidates reach the clinic,” said Li Sun, Ph.D., Founder, President and Chief Technology Officer, ShennonBio. “We have built an integrated technology platform, generated proprietary human datasets and begun translating those capabilities into a pipeline of precision immunotherapies. With $25 million raised to date, and Cyril joining as CEO, we are entering an important new stage for ShennonBio as we advance our first TCE programs toward the clinic.”

“ShennonBio has spent the last several years building a differentiated foundation spanning proprietary human data, target discovery, functional screening, therapeutic design and safety prediction,” said Dr. Konto. “What attracted me to the Company is the opportunity to translate those capabilities into a new generation of precision immunotherapies. I look forward to working closely with Li and the team to advance our pipeline toward the clinic, establish strategic partnerships and build ShennonBio for its next stage of growth.”

The company is developing T-cell engager (TCE) therapies that are designed to help the immune system target cancer cells. Its current pipeline includes programs for small cell lung cancer, ovarian cancer and hepatocellular carcinoma.

ShennonBio has built proprietary datasets covering more than 10,000 tumor samples and 11 million single cells, supported by partnerships with more than 15 institutions.

The company has also appointed Cyril Konto, M.D. as its new CEO. Founder Li Sun, Ph.D., will become President and Chief Technology Officer and will continue leading the company’s scientific strategy and technology development.

The new funding will support ShennonBio’s technology platform and oncology pipeline. Over the next two years, the company plans to advance a development candidate toward IND filing and Phase 1 clinical trials while also exploring licensing and partnership opportunities.

Recommended Stories for You